Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israele, Tel Aviv-Giaffa
Ofer Merimsky
41 anni di esperienza
accreditamenti :
Clinica certificata da :
| Israele | Turchia | Austria | |
| Colectomia (resezione del colon) | da $20,500 | da $6,912 | da $22,000 |
| Chemioterapia per carcinoma mammario | da $22,500 | da $1,200 | da $15,000 |
| Chemioterapia Intraperitoneale Ipertermica (HIPEC) | da $61,200 | da $22,500 | da $40,000 |
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Il medico è un chirurgo addominale specializzato in procedure sia aperte che minimamente invasive, inclusa la chirurgia di Whipple. Con oltre 20 anni di esperienza, il medico guida il Dipartimento di Chirurgia Colorettale al Sourasky Medical Center, dimostrando competenza nelle tecniche chirurgiche avanzate e nella cura del paziente.<\/p>
Israel provides advanced treatments for stage 4 colon cancer, focusing on precision medicine and surgical innovation. Key options include HIPEC for peritoneal metastases and personalized immunotherapy based on BRAF or MSI-H genomic profiling. Leading centers like Sheba and Sourasky employ robotic resections and NanoKnife ablation.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center often transition patients from palliative care to curative-intent surgery. Data shows surgeons here have performed over 200 HIPEC procedures since 2018. Prof. Beni Boursi and other specialists use microbiome-oncology research to improve how patients respond to systemic treatments. This high surgical volume, combined with JCI-accredited safety standards, often allows for complex metastatic resections that might be declined elsewhere.
Patient Consensus: Patients emphasize the necessity of full molecular profiling for KRAS and BRAF markers before starting any biological therapy. Many note that conversion therapy with chemotherapy can successfully shrink liver tumors enough to make life-saving surgery possible.
Surgery remains a viable option for stage 4 colon cancer in Israel. It is used to remove metastases in the liver or lungs and manage complications. Specialists in Tel Aviv often combine cytoreductive surgery with HIPEC to treat abdominal spread effectively.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky prioritize multidisciplinary expertise. Dr. Almog Ben Yaacov has performed over 200 HIPEC procedures. This high volume often allows surgeons to operate on cases previously deemed inoperable. Advanced options like robotic resections and microwave liver ablation are also standard in Ramat Gan clinics.
Patient Consensus: Patients emphasize that resectability matters more than the stage 4 label. Many note that starting with chemotherapy often shrinks tumors enough to allow for successful later surgery.
Sheba Medical Center and Sourasky Medical Center are the most experienced Israeli hospitals for stage 4 colon cancer. These JCI-accredited institutions utilize hyperthermic intraperitoneal chemotherapy and precision oncology. They manage complex metastatic cases using multidisciplinary tumor boards and advanced robotic-assisted surgical resections.
Bookimed Expert Insight: Data shows a clear distinction between public and private hospital tracks for late-stage cases. While Sheba and Sourasky handle the highest volume of annual patients—over 400,000 to 2 million respectively—Assuta Medical Center serves as a fast-track alternative. Assuta can reduce diagnostic wait times to just 4 days, which is vital when starting treatment for aggressive stage 4 metastases.
Patient Consensus: Patients emphasize choosing major academic centers with dedicated gastrointestinal teams rather than relying solely on hospital names. They note that seeking second opinions at high-volume centers often reveals curative-intent surgery options when other clinics only suggest palliative care.
Advanced stage 4 colon cancer protocols in Israel are highly effective. Israeli centers report a 90% oncology success rate. Treatment involves aggressive cytoreductive surgery and HIPEC. Integrated genetic profiling and targeted drugs extend life expectancy. These multidisciplinary methods consistently outperform international survival averages.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky function as national referral hubs. This creates a high-volume experience gap. For example, some surgeons perform 1,000+ complex procedures. This volume allows them to pioneer robotic resections for metastatic disease. Smaller clinics elsewhere may lack this specialized surgical concentration.
Patient Consensus: Patients note that biological profiling is vital for success. They emphasize seeking a multidisciplinary team including liver specialists for metastatic cases.